Onco-Innovations’ Share-Linked Payment Plan Threatens Dilution Even as Nanosoft Boosts ONC010 Manufacturing

The gulf between operational progress and market perception is rarely wider than at Onco-Innovations these days. The oncology biotech has just brought in Nanosoft Polymers to accelerate manufacturing of its lead drug candidate ONC010, yet the stock continues to haemorrhage value, closing Friday at €0.44 — down 1.56% on the day and nearly 49% since the start of the year. The culprit? A recently unveiled C$5 million private placement whose unusual payout structure ties the company’s take directly to its own share price over the next 18 months.

Under a signed term sheet, Onco-Innovations is placing 6,764,070 units with institutional investors at C$0.7392 apiece, each unit carrying one common share and one warrant. The deal is set to close on July 15, 2026, subject to customary conditions and regulatory approvals. What sets this financing apart is the settlement mechanism: the company’s economic interest will be determined across 18 monthly tranches, with each tranche’s value pegged to the future stock price. More specifics are promised at closing — leaving current shareholders to guess how severe the dilution might become if the downtrend persists.

Proceeds are earmarked for precisely the kind of work Nanosoft has been hired to do. Onco-Innovations previously announced it was engaging the polymer specialist to handle process development and analytical characterisation for ONC010, a nanoparticle-based inhibitor of the enzyme polynucleotide kinase phosphatase. The tasks include optimising polymer synthesis, evaluating molecular weight, and assessing production scalability — all steps toward GMP-compliant manufacturing. The company says the fresh capital will also support preclinical testing, the SynoGraph platform, and general working capital.

Should investors sell immediately? Or is it worth buying Onco-Innovations?

So far, the market has brushed aside these technical milestones. Over the past seven days the stock lost 4.13%, and the one-month decline stands at 26.71%. At Friday’s close, the shares traded roughly 25% below their 50-day moving average of €0.59 and nearly 37% below the 200-day average of €0.70. From the 52-week high of €1.33 set last July, the stock has cratered 66.88%. The only floor in sight is the 52-week low of €0.34 hit in March, which leaves a cushion of about 29%.

Technical indicators paint a picture of a stock caught in no man’s land. The 14-day relative strength index sits at 40.5 — neither oversold nor overbought. But the annualised 30-day volatility of over 85% underscores the speculative nature of a preclinical biotech with no approved products or near-term revenue. That volatility amplifies the risk embedded in the financing structure: if the share price keeps sliding, more shares may have to be issued per tranche, accelerating dilution and putting further downward pressure on the price.

Investors are therefore watching two timelines. One is the operational clock — Nanosoft’s polymer development work and the push to get ONC010 into human clinical trials. The other is the July closing date for the private placement, when the full terms of the tranche mechanism will be disclosed. Until then, technical progress on the drug may remain a sideshow as the market wrestles with the mathematical implications of a funding instrument that is, in effect, a bet on its own stock.